Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.

Five patients with Parkinson's disease, unilaterally transplanted with foetal mesencephalic cells into putamen (n=1) or putamen and caudate (n=4), were followed throughout a period of 15-36 months after surgery, according to the recommendations of the core assessment programme for intracerebral transplantations (CAPIT). All these patients exhibited an increase in the fluorodopa uptake in the grafted putamen, which was most significant in the first and last patient of the series. Long-term bilateral improvement of skilled hand movements was observed, starting between the third and sixth month after grafting, and confirmed by the statistical analysis of CAPIT timed tests. A mild to moderate effect on the amount of 'off' time and 'on-off' fluctuations was observed, whereas, apart from one case, no other clear effect on gait, walking and speech was found. One patient included in the study, already suffering slight cognitive impairment, clearly exhibited progression of a dementia process after surgery. Daily living activities were clearly improved in only one of the other four patients. At the end of the study period, all patients needed L-dopa therapy at a similar or higher dose than before grafting, but, in most of them, other dopaminergic drugs were reduced or stopped. All patients exhibited bilateral dyskinesias before grafting that were greatly decreased in intensity a few months after surgery. Delayed asymmetrical dyskinesias, occurring on the side displaying the better motor improvement, i.e. contralateral to the graft, were observed in three patients. These results suggest that neural transplants may influence two central mechanisms involved in motor function and the onset of dyskinesias. These effects are likely to occur through complex interactions with the post-synaptic dopaminergic receptors. The occurrence of dyskinesias might simply reflect increased presynaptic storage and release of dopamine. Alternatively, it might, in part, represent some other long-term deleterious effect of the graft. Since PET-scan data indicate that the reinnervation obtained is sub-optimal, it will be of interest to obtain a larger and denser reinnervation of the host striatum and to try, thereafter, to reduce the dose of L-dopa.

[1]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[2]  A. Lees,et al.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[3]  T. Chase,et al.  Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms , 1994, Annals of neurology.

[4]  Y. Samson,et al.  Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. , 1994, Brain : a journal of neurology.

[5]  J. Obeso,et al.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[6]  P. Kempster,et al.  Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[7]  Richard S. J. Frackowiak,et al.  Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.

[8]  T. Engber,et al.  Motor response complications and the function of striatal efferent systems , 1993, Neurology.

[9]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with parkinson’s disease , 1993 .

[10]  T. Chase,et al.  Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease , 1992, Annals of neurology.

[11]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[12]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[13]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[14]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants , 1992, Annals of neurology.

[15]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.

[16]  Agid Yves Levodopa‐induced dyskinesia , 1992 .

[17]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[18]  Scott T. Grafton,et al.  Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.

[19]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[20]  I. Heuser,et al.  Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease , 1990, Annals of neurology.

[21]  T. Chase,et al.  Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.

[22]  F Lhermitte,et al.  Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? , 1987, Neurology.

[23]  G. Siegel,et al.  Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism , 1971, Journal of neurology, neurosurgery, and psychiatry.